gemcitabine has been researched along with azd 6244 in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bodoky, G; Ciuleanu, TE; La Stella, PJ; Pover, G; Spigel, DR; Tebbutt, NC; Timcheva, C | 1 |
| Cao, P; Chen, E; Green, DE; Hedley, DW; Ibrahimov, E; Knox, JJ; McNamara, MG; Metran-Nascente, C; Serra, S; Tsao, M; Vines, D; Xu, J | 1 |
| Alvaro, D; Bragazzi, MC; Cardinale, V; Carpino, G; Costantini, D; De Rose, AM; Di Matteo, S; Fraveto, A; Gaudio, E; Giuliante, F; Grazi, GL; Lustri, AM; Napoletano, C; Nevi, L; Renzi, A; Semeraro, R | 1 |
| Beare, S; Bridgewater, J; Duggan, M; Lee, D; Lopes, A; McEntee, D; Ricamara, M; Sukumaran, A; Valle, JW; Wasan, H | 1 |
| Arkenau, HT; Blackhall, F; Califano, R; Dean, E; Dymond, AW; Ghiorghiu, D; Greystoke, A; Hossack, S; Lindsay, CR; Md Haris, N; Plummer, R; So, K; Steele, N; Summers, Y; Voskoboynik, M | 1 |
| Chen, E; DeLuca, S; Dhani, N; Doherty, MK; Hedley, D; Jang, R; Knox, JJ; McNamara, MG; O'Kane, GM; Pedutem, T; Sim, HW; Tam, VC; Tang, P; Wang, L | 1 |
4 trial(s) available for gemcitabine and azd 6244
| Article | Year |
|---|---|
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Benzimidazoles; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2012 |
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biliary Tract Neoplasms; Cause of Death; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Retreatment; Treatment Outcome | 2016 |
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Deoxycytidine; Diarrhea; Epistaxis; Fatigue; Female; Gemcitabine; Humans; Lethargy; Lung Neoplasms; Male; Middle Aged; Nausea; Pemetrexed; Protein Kinase Inhibitors; Thrombocytopenia; Vomiting | 2017 |
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Mitogen-Activated Protein Kinase Kinases | 2022 |
4 other study(ies) available for gemcitabine and azd 6244
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biliary Tract Neoplasms; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Molecular Targeted Therapy; Mucins; Neoplasm Transplantation; Phthalazines; Pyridines | 2015 |